Investment case
Revolution Medicines, Inc.
RVMD · 11 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 11 macro, policy, and market developments to Revolution Medicines, Inc. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for RVMD yet, so no modelled value is shown. The RVMD valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run RVMD on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
Direct positive clinical trial data publication in a prestigious journal (NEJM) for a key pipeline asset (darovasertib in RAS-mutant NSCLC), validating the company's pan-RAS inhibitor platform and increasing confidence in future commercialization.
· Moves probability of technical success (pots) for darovasertib, peak sales estimates for darovasertib, discount rate (due to reduced risk)
What changed, by assumption
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR
- 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data | Bullish | 1-3m | 0.90 |
| 2026-09-03 | Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR | Bullish | 1-3m | 0.90 |
| 2026-09-03 | Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC | Bullish | 1-3m | 0.90 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer | Bullish | 1-5y | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer | Bullish | 1-3m | 0.90 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma | Bullish | 1-3m | 0.90 |
| 2026-08-26 | FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor | Bullish | 1-5y | 0.90 |